BNT162b2 mRNA COVID‐19 vaccine‐induced chilblain‐like lesions reinforces the hypothesis of their relationship with SARS‐CoV‐2

作者
Vincenzo Piccolo,Andrea Bassi,Giuseppe Argenziano,Carlo Mazzatenta,Mario Cutrone,Iria Neri,Ramón Grimalt,Teresa Palmira Russo
出处
期刊:Journal of The European Academy of Dermatology and Venereology [Wiley]
卷期号:35 (8): e493-e494 被引量:34
标识
DOI:10.1111/jdv.17320
摘要

We have recently observed a 41-year-old woman who developed chilblain-like lesions (CLL) soon after the second administration of Pfizer (New York, NY, USA) BNT162b2 mRNA COVID-19 Vaccine. The lesions occurred exclusively on the volar aspects of the second and the third fingertip of right hand (Fig. 1). The latency between the administration of the second dose of vaccine and the occurrence of CLL was 24 h. The lesions were extremely painful. History for similar lesions was negative. The patient was otherwise healthy, and her blood examination was within normal ranges except for high levels of IgG anti-spike antibodies, thus determining the positive response to the vaccine. Molecular swab for SARS-CoV-2 showed a negative result. After an initial phase of confusion and disagree among researchers, CLL are nowadays considered a highly likely immune-mediated reaction to SARS-CoV-2 usually observed in healthy asymptomatic young people, whose COVID status is often unremarkable.1-6 It has been postulated that this apparent contradiction could be explained as virus-induced interferonopathy associated with a strong activation of innate immune system and fast clearance of antibodies.7, 8 Recently, Davido et al.9 reported a similar case in a 41-year-old woman developing 'blue toes' after BNT162b2 mRNA COVID-19 vaccine. Differently from our case, the patient developed CLL 4 days after the first dose of the vaccine, leading to avoid the second dose for safety reasons. Another minor difference was related to the location (toes vs. fingers). Pain was as impactful as in our patient, in contrast to what was seen in adolescents, whose CLL were often asymptomatic or poorly symptomatic (itch or mild pain), although sometimes patients complain about intense pain. This is so the second European case of COVID vaccine-induced CLL and the first in Italy. As the number of vaccinated people is still limited, the amount of similar cases is expected to increase over time. A clinical overlap does exist with the non-vaccine-associated CLL, and it seems obvious to think that a relationship with the vaccine is actually present. Chilblain-like lesions are still considered an enigmatic sign, whose association with COVID-19 is a matter of debate. However, the parallel 'epidemic' of CLL contemporary to COVID-19 pandemic is one of the major proofs of their correlation. Basically, it is very important to report postmarketing reactions to vaccines. In the specific case, Pfizer BNT162b2 mRNA COVID-19 vaccine was not associated with the occurrence of CLL in the premarketing registration study10 and this is an important information to add to the plethora of data we are collecting about COVID and vaccine as well. We think that it cannot be casual to observe CLL after COVID vaccine and the reason for that could be the high immune response secondary to the vaccine in some subjects then developing CLL, as a result of strong immune activation against the virus. Although two cases are not enough to establish the cause-effect relationship, we consider the appearance of CLL in patients receiving COVID vaccine as a further unassailable proof of the dependence of CLL from COVID-19. During a period of health uncertainty like the one we are living now, we should be cautious with definitive assertion, but in this specific case, we think that our observation reinforces the hypothesis of a true association between CLL and immune response against SARS-CoV-2. Further larger studies are desirable to confirm our data and to support our hypothesis. The patients in this manuscript have given written informed consent to the publication of their case details. None. The authors have no financial obligations or conflict of interest to declare.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
曾维权完成签到,获得积分10
1秒前
1秒前
11完成签到 ,获得积分10
1秒前
天空发布了新的文献求助10
2秒前
陈敏发布了新的文献求助10
2秒前
乐乐的应助被张贵虎采纳,获得10
3秒前
look发布了新的文献求助10
3秒前
www完成签到,获得积分10
3秒前
ww完成签到,获得积分10
4秒前
小二郎的应助被hanman采纳,获得10
5秒前
所所的应助被梁潇鸿采纳,获得10
5秒前
123发布了新的文献求助10
6秒前
6秒前
dhdx发布了新的文献求助10
7秒前
风吹麦浪的应助被111111采纳,获得10
8秒前
执着大山完成签到,获得积分10
8秒前
骨精龙人完成签到,获得积分10
8秒前
yangshuo完成签到,获得积分20
10秒前
10秒前
科研通AI6.4的应助被Camellia采纳,获得10
10秒前
90发布了新的文献求助10
11秒前
cwy发布了新的文献求助10
11秒前
crane完成签到,获得积分10
11秒前
lily发布了新的文献求助10
12秒前
12秒前
君安发布了新的文献求助10
12秒前
张金森发布了新的文献求助10
12秒前
Ccccc完成签到,获得积分10
13秒前
在水一方的应助被哈基米采纳,获得10
14秒前
jiebao完成签到,获得积分10
14秒前
Zwj发布了新的文献求助10
14秒前
14秒前
15秒前
琳lin完成签到,获得积分10
16秒前
贝尔完成签到,获得积分10
16秒前
17秒前
刘福生发布了新的文献求助10
17秒前
顾矜的应助被害怕的慕晴采纳,获得10
18秒前
小二郎的应助被单薄翠绿采纳,获得10
19秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178102
求助须知:如何正确求助?哪些是违规求助? 9568769
关于积分的说明 21801545
捐赠科研通 7772898
什么是DOI,文献DOI怎么找? 3432613
关于科研通互助平台的介绍 2556748
邀请新用户注册赠送积分活动 2478199